Celltrion Decides to Purchase Additional Treasury Shares Worth 80 Billion KRW to "Enhance Shareholder Value"

Scheduled In-House Purchases Until May 21
Record High Performance Last Year... Stock Considered Undervalued

[Asia Economy Reporter Lee Gwan-joo] Celltrion announced on the 21st that it held a board meeting and decided to repurchase its own shares to stabilize the stock price and enhance shareholder value.

The total number of shares to be repurchased by Celltrion is 507,937 shares, with an estimated acquisition amount of approximately 80 billion KRW. The company plans to acquire the shares through on-market purchases from the 22nd until May 21st.

Previously, Celltrion decided to repurchase its own shares worth about 100 billion KRW and completed the acquisition. With this additional repurchase decision, the total number of shares Celltrion has decided to repurchase this year amounts to 1,055,883 shares.

This additional repurchase was decided based on the judgment that despite steady growth through the biopharmaceutical business, the current stock price level is undervalued. Celltrion recently announced through its earnings disclosure that it achieved the highest-ever annual sales and operating profit since its establishment, with consolidated sales of 1,890.8 billion KRW and operating profit of 753.9 billion KRW.

A Celltrion official stated, “We judged that the stock price is still undervalued compared to the company's intrinsic value, so we proceeded with the additional repurchase of shares as an expression of confidence in business growth and to enhance shareholder value. We will continue responsible management to preserve corporate value and enhance shareholder value.”

Meanwhile, Celltrion Healthcare, an affiliate within the Celltrion Group, also announced a repurchase of its own shares worth about 40 billion KRW on the 18th.

This content was produced with the assistance of AI translation services.